

Rhopressa® (netarsudil) – New drug approval

- On December 18, 2017, <u>Aerie Pharmaceuticals</u> announced the <u>FDA approval</u> of <u>Rhopressa</u> (<u>netarsudil</u>) 0.02% ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route.
- The efficacy and safety of Rhopressa were evaluated in three randomized, active-controlled studies
 of 1,416 patients with open-angle glaucoma or ocular hypertension.
 - The three studies demonstrated up to 5 mmHg reductions in IOP for patients treated with Rhopressa.
 - For patients with baseline IOP < 25 mmHg, the IOP reductions with Rhopressa dosed once daily were similar to those with timolol 0.5% dosed twice daily.
 - For patients with baseline IOP ≥ 25 mmHg, Rhopressa resulted in smaller mean IOP reductions at the morning time points than timolol 0.5% for study visits on days 43 and 90; the difference in mean IOP reduction between the two treatment groups was as high as 3 mmHg, favoring timolol.
- Warnings and precautions of Rhopressa include bacterial keratitis and use with contact lenses.
- The most common adverse reaction with Rhopressa use (53%) is conjunctival hyperemia. Other common adverse reactions (approximately 20%) include corneal verticillata, instillation site pain, and conjunctival hemorrhage.
- The recommended dose of Rhopressa is one drop in the affected eye(s) once daily in the evening.
- Aerie Pharmaceuticals plans to launch Rhopressa by mid-second quarter of 2018. Rhopressa will be available as a 0.02% (0.2mg/mL) ophthalmic solution.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.